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Abstract 
The potential of solid dispersion based formulation using the combination of PEG6000 and 
croscarmellose sodium as drug carrier to enhance the dissolution performance and oral 
bioavailability of Fenofibrate, a poorly water soluble drug was investigated. Fenofibrate is a 
hydrophobic drug in fibrate class of drug which is mainly used in patients at risk of 
cardiovascular disease in the treatment of hypercholesterolemia and hypertriglyceridemia. 
Solid dispersions with different drug-to-carrier ratios were prepared by the physical mixture 
method and solvent method and characterized by dissolution testing within 30minutes. In 
vitro drug release were performed using US pharmacopeia type II apparatus (paddle-
method) in 1000ml distilled water containing 0.75% w/v sodium lauryl sulfate at 75rpm for 
30minutes. UV visible spectrophotometric method was selected for dissolution performance 
investigation at max 290 nm. In physical mixture method F5 (32.5%) and F11 (83%) and in 
solvent method F6 (39%) and F11 (38.5%) have showed good percentage of drug release.  
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1.1 Introduction 
The release of drug substance from the delivery system is depended upon drug absorption 
from solid oral dosage form, the dissolution of drugs under the physiological conditions and 
the drug permeability across the GI tract (Tiwari, Tiwari, Srivastava, & Rai, 2009). 
Dissolution is the rate limiting step in case of absorption for poorly water soluble drugs. So 
increase solubility can increase drug absorption and in result, drug bioavailability. Solid 
dispersion technique is a popular method to improve the dissolution and consequently the 
bioavailability of poorly water soluble drugs (Singh, Baghel, & Yadav, 2011). 
 
 
1.2 Solubility 
Solubility is an important feature of a liquid, solid or vaporous solute that dissolve in a 
liquid, solid or vaporous solvent to obtain a homogeneous solution of the solute in the 
solvent. The solubility of a solute depends in the solvent used, temperature and pressure. 
Saturation concentration measures the level of solubility of a substance in a particular 
solvent in which addition of more solute does not improve the concentration of that solute in 
the solution (Lachman, Lieberman, & Kanig, 1986). 
The unadulterated solvent is normally a liquid or a mixture of two liquids, solid solution and 
even a gas. Solubility measurement widely ranges from infinitely soluble (completely 
miscible- e.g. ethanol in water) to poorly soluble (e.g. silver chloride in water). For poorly or 
very poorly soluble compounds are termed as insoluble compounds in a specific solvent. 
(Clugston & Fleming, 2000). 
Sometimes solubility is mistaken with the capacity to melt or dissolve a substance in the 
dissolution process and for the chemical reaction. For instant, zinc chemically reacts with 
hydrochloric acid to form zinc chloride yet zinc is insoluble in hydrochloric acid. In 
addition, solubility does not depend on the molecular size of components in the formulation 
(Martin, 2011). 
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Solubility broadly expresses in different ways like as a concentration, either by mass, 
molarity, molality, mole fraction etc. the solubility of the solute in this way can be defined 
as the maximum equilibrium amount of solute to dissolve per amount of solvent (Aulton, 
2007) . The major disadvantage in this way is it’s dependability upon the different species 
present in the solvent.  
 
 
1.3 Dissolution 
Poorly water soluble drugs show very negligible availability which next result in their low 
dissolution performance. Consequently, it delays the absorption from the gastrointestinal 
tract. Solubility property of a drug is really an important factor. 
Dissolution performance relies on the solubility and permeability of the oral dosage form. If 
the drug solubility in water is less than 10mg/ml, dissolution is considered as rate limiting 
step for the process of drug absorption.  
Two important points are involved in drug dissolution. One is the transportation of drug 
within the dissolution medium and second is drug release from the dosage form. 
 The factors affecting dissolution are- 
- Physical and chemical properties of drug(e.g. drug’s solubility. drug’s particle size, 
drug’s molecular structure) 
- Characteristics of formulation (e.g. excipients, coating substance) 
- Techniques for dissolution (e.g. types of apparatus, volume, viscosity and pH of the 
dissolution medium etc), (Abdou, 1989)  
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From the Noyesh-whitney equation the hints to improve dissolution rate of drugs specially   
poorly soluble drugs in water can be obtained.  
 
dc/dt = AD(Cs-C)/h 
Where- 
      dc/dt – The rate of dissolution 
A- The available surface area for dissolution 
D- Compound’s dissolution coefficient 
Cs – Compound’s solubility in the dissolution medium 
 C – The concentration of drug in the medium at time t and  
  h- The thickness of the diffusion boundary layer which is adjacent with the surface of the 
dissolving compound  
So to increase dissolution performance of the poor water soluble drugs following approach 
can be used according to the Noyes- Whitney equation- 
-increasing the surface area that is available for dissolution 
- decreasing the particle size of the insoluble drug 
-to optimize the wetting features of compound surface 
-decreasing the boundary layer thickness 
-ensuring sink condition for dissolution 
-administration of drugs in the feed state 
-to improve apparent solubility of drug under physiological relevant conditions 
Among all these possibilities maintaining the sink condition depends on the permeability of 
the gastrointestinal mucosa of the compounds, and on the composition as well as volume of 
the luminal fluids  (Singh, Baghel, & Yadav, 2011). 
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1.4 Biopharmaceuticals Classification System 
Taking into accounts the aqueous solubility, dissolution characteristics of the drug and 
intestinal permeability drug substances are classified into a logical classification that can 
connect both in vitro disintegration and in vivo bioavailability of the drugs. This 
classification is termed as Biopharmaceutics classification system (BCS) (Wagh & Patel, 
2010). 
In BCS point of view, the solubility class obtains by calculating the sufficient volume of 
aqueous medium that is needed to dissolve the highest anticipated dose strength. When the 
highest strength of a drug is soluble in 250ml or less aqueous medium over the pH range 1 to 
8, the drug is called a highly soluble drug. When a test drug has an extent of absorption 
>90% from the intestinal mucosa in humans, the drug is considered as highly permeable 
drugs. 
 Table 1.1: The Biopharmaceutical classification system  
BCS 
Class 
Solubility permeability Absorption 
pattern 
Examples of 
drugs 
Class I High high Well  
Class 
II 
Low High Well Metoprolol, 
propranolol 
Class 
III 
High Low Various Danazol, 
nifedipine 
Class 
IV 
Low Low poor Taxol, 
furosemide 
 
From FDA Guidance for industry (2000) and Amidon et al (1995)  
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Drug dissolves very fast and drug absorption is good in class I drugs. There is no 
bioavailability problem usually in this class for IR drug products. Dissolution is a rate 
limiting step for class II drugs and bioavailability is generally controlled by the drug dosage 
form as well as release rate of the drug substance. Drug is permeability limited in class III 
drugs and bioavailability may not be completed if drug is not released from the dosage form 
and dissolved in the absorption window. Finally, both the dissolution and permeability are 
limited steps and an alternative route of administration is needed for class IV drugs (Shargel, 
Wu-Pong, & Yu, 2012). 
Solid dispersion technique is used to increase the solubility and dissolution performance of 
drugs by using carriers with the target drug. In this case, BCS II drugs are the suitable 
candidates for solid dispersion technique as dissolution is the rate limiting step for the 
absorption of drugs in this class and solid dispersion techniques can show promising 
improvement of the dissolution performance  (Singh, Baghel, & Yadav, 2011).  
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1.5 Definition of Solid Dispersion 
Sekiguchi and Obi in 1961 first proposed the utilization of solid dispersion for increasing the 
dissolution performance and oral bioavailability of poorly water soluble drugs. They 
proposed a solid dispersion formulation as a eutectic mixture where the poorly water soluble 
drugs are dispersed in a physiologically inert and easily water soluble carriers. 
Next, Chiou and Riegelman in 1971 termed solid dispersion as “the dispersion of one or 
more active ingredients in an inert carrier matrix at solid-state prepared by the melting 
(fusion), solvent or melting-solvent method”. 
Mayersohn and Gibaldi in 1966 called solid dispersion as “Solid State”.  
Corrigan defined solid dispersion as “Product formed by converting a fluid drug-carrrier 
combination to the solid state”. 
In current review works Dhirendra et al defined solid dispersion as “a group of solid 
products consisting of at least two different components, generally a hydrophilic matrix and 
hydrophobic drug. The matrix can be either crystalline or amorphous. The drug can be 
dispersed molecularly,in amorphous particles (clusters) or in crystalline particles” (Saffoon, 
Uddin, Huda, & Bishwajit, 2011). 
Some drugs whose solubility performance is enhanced by solid dispersion are- Mifepristone, 
Dyhdroartemisinin, Furosemide, Piroxicam and Others (Ingle, Gaikwad, Bankar, & Pawar, 
2011). 
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1.6 Advantages of solid dispersion 
 
The common advantages of solid dispersion are- 
1. Particles with reduced particle size and increased dissolution rate: 
From the Noyes –whitney equation it is clear that increasing the surface area is one way to 
increase the dissolution of the poor water soluble drugs and this can be obtained through 
reducing particle size. For reducing particle size many common methods are used like 
micronization, recrystallization, and freeze drying and spray drying. For many years 
micronization is used to reduce the particle size in the pharmaceutical industries but the 
main disadvantages are aggregation, agglomeration and poor wettability of the fine particles. 
This leads to have poor dissolution performance. On the other hand, in solid dispersion the 
particle size of the drug is reduced to the minimum level to prevent aggregation and 
agglomeration. Additionally, the solubilizing and wettability properties of the carriers 
contribute to increase the dissolution rate. 
 
2. Particles with improved Wettability: 
The enhancement of solubility of poor water soluble drugs is due to the improved wettability 
of the particles and carriers used in the solid dispersion contribute this property. Moreover, 
addition of surface active agents in the third generation solid dispersion with both drug and 
polymeric carriers greatly enhance the dissolution of the drug particles. 
 
3. Particles with higher porosity: 
Normally the increased porosity can lead to increase drug release profile and the carriers 
used in the solid dispersion usually contribute the porosity of the particles in the 
formulation. 
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4. Drugs in Amorphous state: 
Amorphous state of crystalline drugs which are poorly water soluble has greater water 
solubility due to no energy requirement to break up the crystalline lattice in the dissolution 
process.  Second and third generation solid dispersions are in the amorphous state and thus 
enhance the dissolution performance (Kumari, Chandel, & Kapoor, 2013). 
 
 
 
1.7 Applications of Solid Dispersion 
Some of the applications of solid dispersion are given below- 
 In case of lung transplant patients, it helps to improve immunosuppressive therapy 
through formulation of dry powder solid dispersion for inhalation. This formulation can 
avoid problems associated with the use of local anesthesia and irritating solvents. 
 Solid dispersion formulations accelerate the onset of action of NSAIDS when they are 
needed crucially for acute pain and inflammation. 
 To improve patient comfort and compliance the standard injections of anti cancer drugs 
can be substituted with their oral dosage solid dispersion form (Kumari, Chandel, & 
Kapoor, 2013). 
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1.8 Disadvantages of Solid Dispersion 
2. Problems with dosage form Formulation: 
a. Poor flow and compressibility- 
In sieving and pulverization process, solid dispersion shows complexity. In addition it shows 
compressibility and stability problems. 
To avoid these problems drug granulation follows in-situ granulation method. At first the 
excipients are pre-heated and rotated by using water jacket blender at 700C. Next, the drug 
and carrier mixture is melted at 1000C and is added in the moving power of excipients. After 
that, granules are passed through a 20-mesh sieve and harden at 250C. Finally, magnesium 
stearate (1%) is mixed with the granules and compressed to form tablets. However, wet 
granulation process cannot use here due to the possibility of disruption of its physical 
structure. 
b. Sticking of granules of solid dispersion to Die and Punches: 
The formulations of solid dispersion usually stick to the die and punches. For that, a grease 
proof paper is placed between the metal surface of the die and punches and the granules to 
avoid their direct contact.  
 
3. Problems with manufacturing: 
a. Risk of moisture during cooling process of the solid dispersion: 
In the condensation process during evaporation moisture can be trapped in the solid 
dispersion. A continuous cooling process is done on the surface moving belt or rotating to 
avoid this problem. 
b. Reproducibility of the physical and chemical properties: 
Investigators observe that the manufacturing conditions like rate of heating, the temperature, 
and rate of cooling and cooling methods, pulverization methods, and particle size influence 
the physical and chemical properties of solid dispersion.  
c. Stability problems: 
In hot melt method, a certain fraction of drug sometimes remains dispersed in carrier 
molecularly. That result in the separation of amorphous and crystalline phase.  
 
 11 | P a g e  
 
To overcome such problems some common carriers like PVP, HPMC etc are used. These 
carriers form kinetic barrier to nucleation and the rate of efficiency of the barrier is directly 
proportional to the concentration of the polymer and is independent of the physical and 
chemical properties of that polymer. (Ingle, Gaikwad, Bankar, & Pawar, 2011) 
 (Craig, 2002). 
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1.9 Advantages of Solid Dispersions over the Other Strategies 
The popular strategies to improve the dissolution and bioavailability of poor water soluble 
drugs can be divided into two categories’, they are- 
 Chemical Approaches 
 Formulation Approaches 
Chemical Approaches: 
In this approaches the bioavailability of poorly water soluble drugs are increased by using 
one of the following ways- 
 Salt Formation 
 Introducing a polar group in the Structure 
 Introducing an ionized group. In these ways the active target site of the drugs is kept 
unchanged and resulting in the formation of pro-drugs. 
However, Chemical approaches have such limitations like- 
 Formation of pro-drug is difficult  task 
 Salt formation can only be used for weakly acidic or basic drugs but not for the 
neutral 
 Salt formation can hamper the bioavailability of drugs in vivo due to the formation of 
acidic or basic form 
 In case of NCE, sponsoring company has to perform clinical trials for chemical 
approaches 
 On the other hand, solid dispersions have no such problems. They are easy to produce 
and more applicable. In addition, the formulation of drugs in solid dispersion 
techniques gives option to choose methods among various methods and excipients 
option. Hence, the process provides flexibility to formulate oral dosages form of poor 
water soluble drugs  (Singh, Baghel, & Yadav, 2011). 
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Formulation Approaches: 
Formulation approaches to improve the aqueous solubility of poor water soluble drugs are- 
 Particle Size Reduction 
 Solubilization 
 Solid Dispersion.  
Between the solubilization and solid dispersion , solid dispersion are more preferable 
to most of the patients since it provides the solid oral dosages form then the products 
of solubilization. 
The particle size reduction is most common way to improve the bioavailability of 
poor water soluble drugs on the basis of increase surface area of the drugs, but it also 
has certain disadvantages which limit it’s use to use as a convenient method to 
improve aqueous solubility. The disadvantages are- 
 The limit of the milling or micronization process to reduce particle size is around 2-
5mm which does not frequently increase the bioavailability and the drug release in 
the small intestine. 
 They have poor mechanical properties such as low flow properties and high adhesion 
capacity. 
 The fine particles of the drugs are difficult to handle. 
 Micronizing of drugs can lead to formation of agglomerate of particles which gives 
poor wettability of drugs. 
The water soluble carrier in solid dispersion reduced all the above problems and 
increase dissolution. The drugs need not to be micronized in solid dispersions. Here 
the fraction of drug molecularly disperse in the matrix of carrier and in exposure of 
aqueous media the carrier dissolve where drug releases as fine colloidal. This gives 
greater dissolution rate as a result of sufficient surface area enhancement. Moreover, 
one portion of drug dissolves and saturates the gastrointestinal fluid and rest of the 
drugs precipitates as fine colloidal particles or oily globules of submicron size  
(Singh, Baghel, & Yadav, 2011). 
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1.10 Factors that Influence the Drug Release from the Solid Dispersion 
Nature Of carriers: 
Drug release of poorly water soluble drug from the formulation depends on the nature of the 
carriers used in the formulation. The nature of carriers can be either hydrophilic or 
hydrophobic. So, incorporation of drug in hydrophobic or slightly water soluble carrier 
result in retardation of drug release from the matrix and incorporation of drug in hydrophilic 
or water soluble carriers result in acceleration of drug release. 
 
Drug Carrier Ratio: 
The dissolution rate of drug release increases with the increase proportion of drug carrier but 
it is up to certain limit of the ratio. Beyond the certain limit the rate of the drug dissolution 
decreases.  
 
Method of Preparation: 
Generally solid dispersion prepared by melting method shows greater effect and faster 
dissolution rate the solvent method and co-grinding method. However, among all the 
methods a particular method can show greater effectiveness for a particular solid dispersion 
formulation. 
 
Cooling condition: 
The cooling condition is a important factor specially for the solid dispersion prepared by 
melting method. The rate of cooling whether faster or slower affects the rate of dissolution. 
 
Synergistic Effect of Two Carriers Used: 
If two carriers are used in the solid dispersion technique, their synergistic effect is then 
considered as an important factor. The different properties of two carriers can attribute to 
increase the dissolution performance of the poorly water soluble drugs (Bhusnure, Kazi, 
Gholve, Ansari, & Kazi, 2014). 
 
 
1.11 Classification of Solid Dispersion 
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Solid dispersion is classified on the basis of two criteria- 
 On the basis of carrier used 
 On the basis of solid state structure in the solid state (Bhusnure, Kazi, Gholve, Ansari, & 
Kazi, 2014) 
 
 On the basis of carrier used solid dispersion is classified into three types. They are briefly 
described below- 
 
I. First generation solid dispersion: 
In 1961, Sekiguchi and Obi developed first generation solid dispersion.  First 
generation solid dispersion is prepared by crystalline carriers for instance urea, sugar. 
The preparation of eutectic mixture that was prepared by Sekiguchi and Obi showed 
better drug release which resulted in increased bioavailability than the conventional 
formulations of the same drug. The main reasons of this better drug release are small 
particle size and the better wettability  (Singh, Baghel, & Yadav, 2011). 
The major disadvantage of this type is it leads to the formation of crystalline solid 
dispersion that is thermodynamically more stable then the amorphous ones results in 
slower drug release from the dosage form (Kumari, Chandel, & Kapoor, 2013). 
 
 
II. Second generation solid dispersion: 
A second generation solid dispersion appeared in the late sixties to overcome the 
problems associated with the first generation solid dispersion. Here polymers are 
used instead of crystalline carriers. 
This type originates a homogenous molecular interaction between drug and 
polymeric carriers because they are totally miscible, soluble and possesses higher 
interaction energy between the drug and the carriers. It also reduce particle size and 
gives better wettability to increase the bioavailability of the poorly water soluble 
drugs but works greater than the first generation solid dispersion  (Singh, Baghel, & 
Yadav, 2011). 
The different kinds of polymers used in the second generation are- 
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- Fully synthetic polymers- 
E.g.polyvinylpyrrolidone(povidone),polyethylene glycols, polymethacrylates. 
- Natural product based polymers ( cellulose derivatives, starch derivatives)-
E.g. hydroxypropylmellylcellulose, ehtylcellulose, hydroxypropylcellulose, 
cyclodextrins  (Bhusnure, Kazi, Gholve, Ansari, & Kazi, 2014). 
 
 
III. Third generation solid dispersion: 
The third generation solid dispersion appears to solve the problems with first and 
second generation. Second generation solid dispersion has some common problems 
like recrystallization, chemical and physical instability etc. fortunately addition of 
surfactants with the second generation carriers can solve almost all the problems 
associated with second generation solid dispersion. So, adding surface active agent 
with the polymeric carriers is referred to as third generation solid dispersion. In third 
generation solid dispersion, the formulation can be stabilized for at least sixteen 
month. It also helps the formulation containing polymeric carriers to prevent 
recrystallization and precipitation which can be occurred from the agglomeration of 
much larger hydrophobic particles  (Singh, Baghel, & Yadav, 2011).  
The common surfactants used in the third generation solid dispersion are inulin, 
inutec SP1, compritol 888 ATO, gelucire 44/14 and poloxamer 407 (Bhusnure, Kazi, 
Gholve, Ansari, & Kazi, 2014). 
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 On the basis of solid state structure, solid dispersion is classified into 
following ways- 
A. Drug and polymer exhibiting immiscibility in the fluid state: 
The immiscible mixtures of drug and polymer in their fluid state are 
grouped in this class. In addition, the mixture of drug and polymer 
normally do not exhibit miscibility on the solidification of the fluid state 
and phase separation can be occurred. They may enhance the dissolution 
performance through following ways- 
-modifying the morphology of drug and/or polymer because of physical 
transformation. 
- intimate drug/polymer mixture 
-enhancing surface area 
However, the rate of solidification of mixture and the rate of 
crystallization process of drug and/or polymer bias the formation of 
crystalline solid dispersion and amorphous solid dispersion. 
 
B. Drug and polymer exhibiting miscibility in the fluid state: 
The miscible mixtures of drug and polymers in their fluid state may or 
may not show miscibility and phase separation in their solidification 
process. Additionally, this state influences the structure of solid 
dispersions.  
 
C. Eutectic Mixtures: 
In 1961 Sekiguchi and Obi described eutectic mixture as solid dispersion. 
When drug and polymer are miscible in their molten state but on cooling 
they form two separate components with negligible miscibility is referred 
to as eutectic mixture. Generally, the melting point of the eutectic mixture 
is lower than the components of the mixture. Here the mechanism is to 
increase the surface area of the drug to enhance the bioavailability.  
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D. Crystalline solid dispersion: 
In the crystalline solid dispersion, the rate of drug crystallization from the 
drug/polymer miscible mixture is greater than the rate of the solidification 
of the drug/polymer in their fluid state. 
 
E. Amorphous solid dispersion: 
Amorphous solid dispersion can be formed if the drug crystallization is 
not allowed by the cooling rate of drug/polymer cooling fluid mixture. 
This state can also be referred as “solidified-liquid” state. Still, the 
amorphous solid dispersion has potential to form a more stable and less 
soluble crystalline formulations. 
 
F. Solid solution: 
When drug/polymer mixture is miscible in both fluid and solid state, it is 
called solid solution. Generally there are two types of solid solution-
1.Amorphous solid solution 
                         2. Crystalline solid solution 
1. Amorphous solid solution: 
Amorphous solid solutions are those where the drugs are molecularly dispersed in the 
carrier matrix and miscible in both fluid and solid state. This type of solid dispersion is 
effective as it increases the surface area in greater rate and enhances the dissolution 
performance. Moreover, it enhances physical stability of the formulation through 
preventing crystallization by minimizing molecular mobility.  
2. Crystalline solid solution : 
When a crystalline drug is trapped in crystalline carrier with miscibility in both fluid and 
solid state then the solid dispersion is termed as crystalline solid solution.  
Again on the basis of miscibility solid solution is divided into two types- 
1. Continuous solid solution 
2. Discontinuous solid solution 
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1. Continuous solid solution: 
The two components are miscible in their solid state in all proportion in case of 
continuous solid dispersion.  
2. Discontinuous solid solution: 
In discontinuous solid dispersion, the two components are immiscible in their 
intermediate composition but miscible at extremes of composition. 
Furthermore, on the basis of the size of the molecule of the two components, solid 
solution is divided into two types. They are- 
1. Substitutional solid solution 
2. Interstitial solid solution 
 
1. Substitutional solid solution: 
In the crtstal lattice the solute molecules substitutes for the solvent molecule to obtain 
substitutional solid solution and the molecular size of the two components should not 
exceed 15%. 
2. Interstitial solid solution: 
When the solute molecule occupies the interstitial space in the solvent lattice, interstitial 
solid solution can be obtain. Here, the solute is referred as the guest and the solvent is 
referred as host. For the interstitial solid solution the ideal molecular diameter of the 
solute should be less than 0.59 than the molecular diameter of the solvent. In addition, 
the volume of the solute molecules should be less than 20% than the volume of the 
solvent molecules (Bhusnure, Kazi, Gholve, Ansari, & Kazi, 2014). 
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1.12 Methods of Solid Dispersion 
There is numerous method of solid dispersion. Among them the most common methods are 
described briefly in below- 
1. Kneading Technique 
In this method, at first carrier and drugs are weighted separately. Then carriers are wetted 
with water and turn into paste. Next, drugs are added to the paste and kneaded for a 
particular time. Lastly, the mixture is dried and passes through sieve.  
 
2. Solvent evaporation method 
In solvent evaporation method drugs and carrier are weighted and dissolve in a suitable 
organic solvent. After that the solvent is evaporated. Finally, the solid mass is grounded, 
sieved and dried. 
 
3. Co-precipitation method 
Co-precipitation method involves both water and solvent. Firstly, drug is dissolve in a 
suitable organic solvent and carrier is dissolve in water. Next, the aqueous solution of 
carrier is added to the drug solution. Then, the solvent is evaporated through heat and 
pulverized by using mortar and pestle. Finally, the mixture is dried and sieved. 
 
4. Melting method 
Drugs and carrier are weighted perfectly. Next, the drug and carrier are mixed 
homogenously by the help of mortar and pestle. Then the whole mixture is melted 
through heating at or above the melting point of all the components to get a homogenous 
dispersion. After that, the mixture is cooled, pulverized in mortar and pestle, sieved and 
dried. 
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5. Co-grinding method 
This is one of the simple methods of solid dispersion. In this method the physical mixture 
of drug and carrier is obtained through mixing in blender for some time at a particular 
speed. Finally, the mixture is pulverized, sieved and stored in dry place at room 
temperature. 
 
6. Gel entrapment technique 
Here carrier is dissolved in suitable organic solvent and made it into transparent and clear 
gel. Then the drug is dissolved in the gel by sonication for few minutes. Next, the solvent 
is evaporated under vacuum condition. Finally the solid dispersion is reduced in size by 
mortar and sieved. 
 
7. Spray-Drying Method 
Spray dry method is a new approach. In this method, drug is dissolve in suitable organic 
solvent and carrier is dissolved in water. Afterwards, solution is mixed through sonication 
or other suitable methods to get a clear solution. In the final step the solution is spray 
dried using spray drier. 
 
8. Lyophilization Technique 
This is a costly procedure. Lyophilization technique is also regarded as an alternative 
method of solvent evaporation. It is a molecular mixing technique where both drug and 
carrier are co-dissolve in a common solvent. Finally the solution is frozen and sublimed 
to achieve a lyophilized molecular dispersion. 
 
9. Electrospinning Method 
In future this technique can be used in the preparation of solid dispersion. The technique 
is the combination of the dispersion technology with the nanotechnology. The stream of 
liquid of solid dispersion solution is given a potential between 5 and 30 kV. As a result 
fibers of submicron diameters are produced. The fibers can be collected on a screen after 
the evaporation of the solvent. Since the technique is simplest and cheapest for producing 
nanofibers and controlling the release of biomedicine, the technique has great potential. 
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10. Dropping method solution 
In 1997, Ulrich developed the dropping method. The method is said to facilitate the 
crystallization process of various chemicals and produces round shape particle in solid 
dispersions. At first, physical mixture of drug-carrier is melted at or above the melting 
point of the components through heating. Next the melted solid dispersion is pipette and 
is dropped on to a plate. Therefore, it produces round particles upon solidification. The 
use of carriers that solidifies at room temperature facilitates the process. As it does not 
involve any use of solvent it can overcome problems associated with solvent evaporation 
method. However, the size and shape of the particles can be influenced by the pipette 
size, temperature require to solidify and viscosity of the melted mixture. 
 
11. Direct Capsule Filling 
Liquid melt of solid dispersions can directly fill in to the hard gelatin capsule. As a result 
it can avoid the problems associated with grinding procedure like changes in the 
crystallinity of the drug. It can also avoid cross contamination and operator exposure in 
the dust-full environment. In addition, it facilitates better fill weight and content 
uniformity  (Singh, Baghel, & Yadav, 2011) (Kumari, Chandel, & Kapoor, 2013) 
(Saffoon, Uddin, Huda, & Bishwajit, 2011). 
  
12. Physical Mixture Method 
It is one of the simple methods in solid dispersion technique but not so effective. 
However, homogenous mixture of drugs and carriers can be obtained from drugs and 
carriers are weighed and then mixing them in a mortar and pestle by triturating. The 
resulted physical mixtures are passed through 44-mesh sieve (generally) and are stored in 
desiccators until used for further (Bonthagarala, Nama, Nuthakki, Kiran, & Pasumsrthi, 
2014). 
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1.13 Criteria for the selection of carriers 
In solid dispersion the performance of the dissolution is improved due to the properties of 
the carriers. Selection of a suitable carrier or mixture of carriers for a particular water 
insoluble drug follows some common criteria. They are- 
 They should be water soluble and also readily soluble in gastrointestinal 
fluids 
 They should be physiologically inert 
 The melting point of the formulation with drug and carrier should be less than 
of the drug 
 The carrier should have thermal stability at melting temperature 
 They should have low vapor pressure 
 The carriers should have high molecular weight 
 They must be non-toxic  (Tiwari, Tiwari, Srivastava, & Rai, 2009) 
 
 
1.14 Polymers used in the Solid Dispersion 
Sugars: 
Sugars are highly water soluble but due to the toxicity issues, they are not widely used in the 
solid dispersion preparation. 
Sugars that are commonly used in the solid dispersion formulation are dextrose, sucrose, 
lactose, sorbital, maltose, mannitol, galactose. 
 
Acids: 
Several researches found out that the rate of drug release can be increased twenty times with 
the use of these organic acids. Moreover, they can also increase stability of the formulation 
like citric acid shows improved stability in inhalation formulation of spray-dried insulin 
powder. 
E.g. citric acids, succinic acids, tartaric acids etc 
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Polymeric materials: 
a. PEGs are the polymers of ethylene oxide and have MW in the range 200 ± 3, 00,000. 
Generally their water solubility is good but the solubility can decrease with MW. The 
major advantages of PEGs are they are soluble in many organic solvent and their melting 
point (m.p.) remains under 650C. Production of product with sticky consistency is the 
main disadvantage of lower MW PEGs. 
b. Polyvinyl pyrrolidone (PVP)- 
PVP is the polymerization of vinylpyrrolidone and their MW ranges from 2500 to           
3,00,000. The advantageous points of PVP are their good solubility in many organic 
solvents, good solubility in the water and can improve the wettability of the dispersed 
substances. Additionally the chain length is an important factor for increasing the water 
solubility of poor water soluble drugs. The aqueous solubility of the PVPs decreases and 
they become less viscous with the increased chain length.  
c. Cellulose derivatives- 
Naturally occurring polysaccharides are known as cellulose and they have higher molecular 
weight unbranched chains which forms through joining the saccharide units linking by β-1, 
4-glycoside bonds. 
Common cellulose derivatives are MC, HPC, HPMC, pectin 
 
Emulsifiers: 
Through two mechanisms namely solubilization of the drugs and improvement of wettability 
emulsifiers increase the dissolution performance that results in increase aqueous solubility of 
poor water soluble drugs. However for exhibiting toxicity they are used with the other 
carriers in the solid dispersion preparations.  
E.g. poloxomers, gelucire 44/14 and other grades of gelucire etc. Bile salts and their 
derivatives are natural emulsifiers. 
 
Surfactants- 
Surfactants are used in the third generation solid dispersion to improve the surface area of 
the particles to enhance the aqueous solubility of poorly water soluble drugs in greater way. 
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E.g. poloxamers, Tweens (polyethoxylated sorbitan esters), Spans (sorbitan esters), 
polyoxethylene stearates etc. 
 
Miscellaneous: 
Other carriers are urea (the end product of human protein metabolism), urethanes (a class of 
synthetic elastomers), and polyurethane (a polymer containing a chain of organic units 
joined by urethane or carbamate links) (Kumari, Chandel, & Kapoor, 2013). 
 
 
1.15 Reasons for Choosing Combination of PEG6000 and Croscarmellose 
Sodium 
Firstly, PEG6000 has well an aqueous solubility and miscible with most of the organic 
solvent. In addition, its melting point is in 55-65oC range (Kumari, Chandel, & Kapoor, 
2013) and has no incompatibility with croscarmellose sodium (Rowe, Sheskey, & Quinn, 
2009). Furthermore, the polymer is inexpensive and available. 
Secondly, croscarmellose sodium is a super disintegrant. It facilitates the water uptake 
through promoting liquid penetration, using capillary forces to suck water into the pores of 
granules or tablets (Aulton, 2007). Moreover, it does not show any incompatibility with 
PEG6000 in normal condition (Rowe, Sheskey, & Quinn, 2009). Croscarmellose sodium is 
also inexpensive and available. 
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1.16 Fenofibrate 
1.16.1 Description 
Fenofibrate, isopropyl ester of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl propanoic acid, is 
hydrophobic in nature and has molecular weight of 360.84. Fenofibrate is white or almost 
white, crystalline powder. It is practically insoluble in water, slightly soluble in alcohol and 
very soluble in methylene chloride (BP, 2005). Its melting point is 79-82oC.    
1.16.2 Clinical Pharmacology 
Fenofibrate is a lipid lowering drug and fall under fibrates group of hypolipidaemic drugs. 
Fibrates are isobutyric acid derivatives. Fenofibrate is a second generation prodrug fibric 
acid derivatives. They primarily activate lipoprotein lipase (a key enzyme in the degradation 
of VLDL). Consequently, it lowers the circulating TGs. Lipropotein lipase production and 
fatty acid oxidation increase through the activation of PPAR- (a gene transcription 
regulating the expression of receptor in liver, fat and muscles). In addition second generation 
fibrates like fenofibrates also mediate enhanced LDL receptor expression in liver  (Singh, 
Baghel, & Yadav, 2011).  
Fenofibrate is most effective in type III, IV and V hyperlipoproteinaemia. The drug may use 
as an adjuvant drug in type IIb patients. The reported adverse effects are myalgia and 
hepatitis rashes (Tripathi, 2008). 
1.16.3 Fenofibrate as an Ideal Candidate for Solid Dispersion 
Fenofibrate is an ideal candidate for solid dispersion as it is in BCS class II drug that have 
low aqueous solubility and high permeability. Hence, bioavailability is a rate limiting step 
for the absorption of drug from the gastrointestinal tract.  The drug is practically insoluble in 
water where it has higher lipophilicity (log= 5.24). Recently this drug is marketed in 85 
countries and available mostly in micronized form  (Singh, Baghel, & Yadav, 2011).  
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1.17 Literature Review 
Dissolution enhancement work on Fenofibrate using the combination of croscarmellose 
sodium and PEG6000 has not been done yet. Very few works have been done with 
PEG6000 using physical mixture method and solvent method with ethanol. 
In research work of “Study on the effect of different polymers on in-vitro dissolution profile 
of Fenofibrate by solid dispersion technique” in “Journal of Applied Pharmaceutical 
Science” the solid dispersion with PEG6000 was carried out using solvent method. The 
formulation containing 1200mg PEG6000 has showed greater dissolution 100.61% within 
60 minutes of dissolution (Saffoon, Uddin, Huda, & Bishwajit, 2011). 
In “Solubility enhancement and solid state characterization of Fenofibrate solid dispersions 
with polyethylene glycol 6000 and 8000” in “Journal of Pharmacy Research” physical 
method and melting method were carried out at drug and PEG6000 ratio 1:1, 1:2, 1:3 and 
1:5. It has been found out that the dissolution performance increases with increasing amount 
of PEG6000 (Bonthagarala, Nama, Nuthakki, Kiran, & Pasumsrthi, 2014). 
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Chapter 2:  
Methodology 
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2.1 List of Instruments, Apparatus and Glass Wares 
 
 
       Table 2.1: List of instruments and equipment used in the analysis 
 
Serial 
Number 
Instrument Model/Manufacturer Country of 
Origin 
1 Electronic balance Shimadzu Japan 
2 Dissolution Tester Logan Instruments 
Corp.,UDT-804 
USA 
3 UV-Visible 
Spectrophotometer 
Hitachi Japan 
4 Water suction 
filtration 
Shimadzu Bangladesh 
 
 
 
 
 
 
 
       Table 2.2: List of apparatus and glass wares used in the experiment 
 
Serial 
Number 
Name Specification 
1 Volumetric flask 10ml 
2 Pipette(graduated & 
volumetric) 
1ml,10ml 
3 Beakers 10ml,50ml,100ml 
4 Measuring cylinder  100ml,1000ml 
5 Pipette filler Bangladesh 
6 Mortar & Pestle Small 
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2.2 Preparation of 0.72% sodium lauryl sulphate 
 
7.2g of sodium lauryl sulphate was dissolved in 1000ml of distilled water to produce 1litre 
0.72% dissolution media. 
 
2.3 Preparation of Solid Dispersion by Solvent Method 
 
200mg of seven times Fenofibrate were correctly weighed and were kept in seven 10ml 
beakers separately. 8ml of ehanol was added in each formulation (F4, F5, F6, F8, F9, F10 
and F11). Drug was completely dissolved in the solvent. Different ratios of PEG6000 and 
croscarmellose sodium were added in the solution at specific amount according to 
formulations. Then they were sonicated for five minutes. All solutions were kept at normal 
environment for one day. When the solutions were evaporated completely, they were 
crushed in morter and pestle. 
 
2.4 Preparation of Physical Mixture Method 
Physical mixture of Fenofibrate with different combination of PEG6000 and croscarmellose 
sodium of from F1 to F13 was prepared separately. In each formulation Fenofibrate and the 
combine form of PEG6000 and croscarmellose sodium at specific amount according to the 
formulation were accurately weighed, pulverized and then mixed thoroughly by light 
tituration for five minutes in small mortar and pestle for each formulation until homogenous 
mixture was obtained.  
 
 
 
 
 
 
 
 31 | P a g e  
 
2.5 List of Formulation Code with their Compositions and Respective 
Method 
Table 2.3 is showing the composition of each formulation both in physical mixture method 
and solvent evaporation method. Here the pure drug ratio is always same for each 
formulation. Only thing differ is the different ratio of combination of PEG6000 and 
croscarmellose sodium. 
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Table 2.3: Name of Methods, Compositions & code of Formulation, Ratio of drug and excipients  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name of 
Methods 
Compositions Drug: Polymer: 
Disintegrate 
Ratio(mg) 
Formulation Code 
 
 
 
 
Physical 
Mixture 
Fenofibrate 
(200mg) 
_ PD 
 
 
Fenofibrate: 
PEG6000: 
Croscarmellose 
Sodium 
200:2:5 F1 
200:5:10 F2 
200:10:20 F3 
200:15:30 F4 
200:20:40 F5 
200:30:60 F6 
200:80:160 F7 
200:40:20 F8 
200:50:25 F9 
200:60:30 F10 
200:70:35 F11 
200:80:40 F12 
   200:160:80 F13 
 
 
Solvent 
Method 
 
 
Fenofibrate: 
PEG6000: 
Croscarmellose 
Sodium 
200:15:30 F4 
200:20:40 F5 
200:30:60 F6 
200:40:20 F8 
200:50:25 F9 
200:60:30 F10 
200:70:35 F11 
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2.6 Pictures & Images of the Instruments 
 
 
 
 
 
Figure 2.1: Picture showing an electronic balance 
 
 
 
 
Figure 2.2: Picture showing UV-Visible spectrophotometer 
 
 
 34 | P a g e  
 
 
 
Figure 2.3: Picture showing dissolution tester 
 
 
Figure 2.4: Picture showing the paddle of dissolution tester 
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2.7 In vitro Dissolution Study 
   2.7.1Principle 
Release rate of fenofibrate solid dispersions are carried on according to the general 
procedure of United States Pharmacopoeia (USP). Samples of dissolution fluid are 
withdrawn and analyzed by UV Spectrophotometer. The measurement is done at the 
wavelength at which the absorption is maximum. By comparing with absorbance of 
standard solution, the amount of active fenofibrate in solid dispersions released is 
calculated. 
          2.7.2 Conditions 
 
                  Table 2.4: Conditions in dissolution testing 
 
Apparatus USP 2 Paddle 
Dissolution medium 0.72% Sodium lauryl sulfate in distilled 
water, 1000mL, deaerated. 
Temperature 36.7oC (±0.5) 
Stirring Speed 75rpm 
Time 30 inutes 
 
 
                  2.7.3 Preparation of Standard Solution 
10mg of working standard of Fenofibrate was weighed and transferred into a clean 
and dry 10ml volumetric flask. Then 10ml of methanol was added to the volumetric 
flask and shaken properly to get concentration about 1000µg/ml. 2ml of above stock 
solution was diluted to 10ml with methanol in another 10ml volumetric flask to get a 
secondary stock solution of 200µg/ml. From this stock solution series of dilutions 
with concentration of 5, 10, 15, 20, 25, 30µg/ml in methanol were prepared in 
separate volumetric flasks. 
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2.7.3Standard Curve of Fenofibrate 
 
      Table 2.5: Standard Curve of Fenofibrate 
Concentration (µg/ml) Absorbance 
5 0.1 
10 0.21 
15 0.32 
20 0.434 
25 0.54 
30 0.62 
 
 
 
 
 
 
 
Figure 2.5: Standard curve of Fenofibrate 
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2.7.1 Preparation of Sample Solutions  
1000ml of dissolution media was placed into each of six dissolution vessels and 
the temperature was set to 370C (±0.5). Solid dispersion formulations were 
transferred to each six baskets. The baskets were immersed into the medium to a 
distance 25±2 mm between the basket and bottom of the vessel. The apparatus 
was started to operate at the specified rpm. At the end of 30min, 10ml samples 
were withdrawn from each vessel. 1ml sample from that withdrawn sample was 
taken in a 10ml volumetric flask and 9ml media was added to it. This was done 
for every withdrawn sample to get a concentration of 20µg/ml.  
Then the absorbance of the above solution in a 1cm silica cell were measured at 
the wavelength of maximum absorbance at 290mm(according to USP) by UV-
visible spectrophotometer using media as blank. The percentage of drug release 
from the solid dispersion formulations were calculated with the help of straight-
line equation obtained from the standard curve of Fenofibrate. The dissolution 
was continued for 30 minute in the in-vitro condition. 
 
2.8 Collection of Samples 
The source of Fenofibrate was Nexchem pharmaceutical company, china. PEG 6000 and 
Croscarmellose sodium were obtained pharmaceutical technology laboratory in Pharmacy 
department of BRAC University. All other reagents and solvent used were of analytical 
grade. 
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Chapter 3: 
Result and Discussion 
 
 
 
 
 
 
 
 
 
 39 | P a g e  
 
3.1 In Vitro Dissolution Study Results 
 
       Table 3.1: Table showing percentage of drug release in physical method from F1 to F7 
Physical Mixture 
Formulation Code % of Drug Release 
PD 
8.9 
F1 
10.5 
F2 
29 
F3 
29.5 
F4 
31 
F5 
32.5 
F6 
22 
F7 
22.5 
 
 
 
Figure 3.1: The line showing the increase and decrease of the percentage of drug release in 
physical Mixture from F1 to F7 
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Figure 3.2: Bar chart showing the percentage of drug release in physical mixture from F1 to 
F7 
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      Table 3.2: Table showing percentage of drug release in physical mixture from F8 to F13 
 
 
 
 
 
 
Figure 3.3: The line showing the increase and decrease of the percentage of drug release in 
physical mixture from F8 to F13 
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Physical Mixture 
Formulation Code % of Drug release 
PD 8.9 
F8 
40 
F9 
42.5 
F10 
47.5 
F11 
83 
F12 
35 
F13 
25.5 
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Figure 3.4: Bar chart showing the percentage of drug release in physical mixture from F8 to 
F13 
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       Table 3.3: Table showing percentage of drug release in Solvent method from F4 to F6 
Solvent Method 
Formulation Code % of Drug Release 
PD 8.9 
F4 30.5 
F5 32.5 
F6 39 
 
 
 
 
 
Figure 3.5: The line showing the increase and decrease of the percentage of drug release in 
Solvent method from F4 to F6 
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Figure 3.6: Bar chart showing the percentage of drug release in Solvent Method from F4 to 
F6 
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       Table 3.4: Table showing percentage of drug release in Solvent method from F8 to F11 
Solvent Method 
Formulation Code % of Drug Release 
PD 8.9 
F8 24 
F9 28 
F10 33 
F11 38.5 
 
 
 
 
 
 
Figure 3.7: The line showing the increase and decrease of the percentage of drug release in 
Solvent method from F8 to F11 
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Figure 3.8: Bar chart showing the percentage of drug release in Solvent Method from F8 to 
F11 
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    Table 3.5: Table showing Difference percentage of drug release in Solvent method and 
Physical Method from F4 to F6 
Formulation Code 
% of Drug Release in 
Solvent  Method 
% of Drug Release in 
Physical Mixture 
F4 30.5 31 
F5 32.5 32.5 
F6 39 22 
 
 
 
 
 
 
Figure 3.9: Bar Chart showing Difference in percentage of drug release Between Solvent 
method and Physical Method from F4 to F6 
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   Table 3.6: Table showing Difference percentage of drug release in Solvent method and 
Physical Method from F8 to F11 
Formulation Code 
% of Drug Release in 
Solvent SD Method 
% of Drug Release in Co-
grinding SD Method 
F8 24 40 
F9 28 42.5 
F10 33 47.5 
F11 38.5 83 
 
 
 
 
Figure 3.10: Bar Chart showing Difference in percentage of drug release Between Solvent 
method And Physical Method from F8 to F11 
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3.2 Discussion 
The prime aim of this project is to overcome the solubility problems of Fenofibrate through 
two easy and inexpensive methods in solid dispersion named physical mixture method and 
solvent evaporation method. Different formulations with different ratio of polymer and 
disintegrant mixture were designed. Percentages of drug release of each formulation were 
calculated from the slope of the appropriate plot and regression coefficient (r2) was 
determined. 
Table 3.1 is showing the percentage of drug release in physical mixture method of solid 
dispersion from F1 to F7 within 30mintutes. All the formulations showed a small extent of 
dissolution improvement from the plain drug. Among these formulations F5 showed higher 
percentage of drug release than other and it was 32.5%. It was seen that from F1 to F5 the 
percentage of drug release were increasing but from F6 to F7 the percentage of drug release 
has fallen to some extent. So it can be said, in the ratio between PEG6000 and 
croscarmellose sodium with drug, if the amount of croscarmellose sodium is higher than the 
PEG6000 then the percentage of drug release increases. However, from 30:60 ratio of 
PEG6000 and croscarmellose sodium with same amount of drug, the percentage of drug 
release has fallen. It can be concluded that up to 20:40 ratio the percentage of drug release 
increase in physical mixture method but from 30:60 the percentage of drug release falls. As 
a hydrophilic polymer PEG6000 offers usually better surface area for the hydrophobic 
Fenofibrate drug and croscarmellose sodium as a super disintegrants break up granules into 
primary powder particles in order to increase surface area and in addition to facilitate water 
uptake. Still high swelling disintegrant like sodium croscarmellose should be given in low 
concentration in the formulation or up to (1-5) % (Aulton, 2007). Otherwise the high 
concentration of disintegrants make too much fine particles that aggregates and produces 
lump instead of deaggregation and affects the dissolution and oral bioavailability. In result, 
with high concentration of croscarmellose sodium the percentage of drug release falls. In 
figure (3.1 and 3.2) up and downing of the percentage of drug release from F1 to F7 has 
shown. 
Next, table 3.2 is showing the percentage of drug release in physical mixture method of solid 
dispersion from F8 to F13 within 30mintutes. All the formulations showed a small extent of 
dissolution improvement from the plain drug. Among these formulations F11 showed higher 
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percentage of drug release than all F1 to F13 and it was 83%. It was seen that from F8 to 
F11 the percentage of drug release were increasing but from F12 to F13 the percentage of 
drug release has fallen to some extent. So it can be said, in the ratio between PEG6000 and 
croscarmellose sodium with drug, if the amount of the PEG6000 is higher than 
croscarmellose sodium then the percentage of drug release increases. However, from 80:40 
ratio of PEG6000 and croscarmellose sodium with same amount of drug, the percentage of 
drug release has fallen. It can be concluded that below 80:40 ratio the percentage of drug 
release increase in physical mixture method but from 80:40 the percentage of drug release 
falls. The falling of percentage of drug may be due to the higher concentration of both 
polymer and disintegrant that form lumps and interact drug release from its dosage form. In 
figure (3.3 and 3.4) up and downing of the percentage of drug release from F8 to F13 has 
shown. 
Several mechanisms may be possible to the enhanced release of Fenofibrate in the physical 
mixture method in solid dispersion. The faster dissolution of the drug from the solid 
dispersions is attributed to the enhancement of wettability as hydrophilic carrier PEG6000 
and disintegrant croscarmellose sodium are used and decrease in the aggregation of the 
hydrophobic drug particles. 
Table 3.3 is showing the percentage of drug release in solvent evaporation method of solid 
dispersion from F4 to F6 within 30mintutes. All the formulations showed a small extent of 
dissolution improvement from the plain drug. Among these formulations F6 showed higher 
percentage of drug release than other and it was 39%. It was seen that from F4 to F6 the 
percentage of drug release were increasing. So it can be said, in the ratio between PEG6000 
and croscarmellose sodium with drug and solvent, if the amount of croscarmellose sodium is 
higher than the PEG6000 then the percentage of drug release increases. In figure (3.5 and 
3.6) the gradual increasing of the percentage of drug release from F4 to F6 has shown. 
Table 3.4 is showing the percentage of drug release in solvent evaporation method of solid 
dispersion from F8 to F11 within 30mintutes. All the formulations showed a small extent of 
dissolution improvement from the plain drug. Among these formulations F11 showed higher 
percentage of drug release than other and it was 38.5%. It was seen that from F8 to F11 the 
percentage of drug release were increasing. So it can be said, in the ratio between PEG6000 
and croscarmellose sodium with drug and solvent, if the amount of the PEG6000 is higher 
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than croscarmellose sodium then the percentage of drug release increases. In figure (3.7 and 
3.8) the gradual increasing of the percentage of drug release from F8 to F11 has shown. 
Increased dissolution of Fenofibrate in solvent evaporation method of solid dispersion could 
be probable reduction in its particle size, wetting of the hydrophobic particles and 
amplification of its solubility by PEG6000 and croscarmellose sodium. Furthermore, due to 
the uniform distribution when this system comes in contact with an aqueous dissolution 
medium, the hydrophilic carrier dissolves and results in fine particles drugs with increased 
surface area. Moreover, other factors can be absence of aggregation or crystal growth of 
drug during dissolution. 
Between physical mixture and solvent evaporation method, physical mixture method 
showed better result than solvent method in F4, F5, F6, F8, F9, F10, and F11. The 
comparison is shown in table (3.5 and 3.6) and figure (3.9 and 3.10). This is because drug, 
polymer and disintegrant have any incompatibility with ehanol and it lowers the percentage 
of drug release from the physical mixture in case whether the amount of disintegrant 
increases or PEG6000 increases. 
In conclusion it can be said that, though in both methods of the solid dispersion the 
percentage of drug release within 30minutes have increased to some extent but only 
F11(83%) prepared in physical mixture method meet the specifications as the percentage of 
Fenofibrate release within 30minutes should be 80% according to USP. 
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4.1 Conclusion 
Physical mixture method and solvent method are two simple and effective methods in solid 
dispersion for increase dissolution performance and solubility. The present study was carried 
out to investigate the utility of the combination of PEG6000 and croscarmellose sodium in 
physical mixture method and solvent method. All the preparations in both physical mixture 
method and solvent method have showed better drug dissolution than that of plain drug 
within 30minutes. It can be assume that both techniques increase the solubility of the 
Fenofibrate in aqueous medium. Therefore, the percentage of drug release showed better 
dissolution within 30 minutes. For further investigation with the combination of PEG6000 
and croscarmellose sodium and Fenofibrate, this work can help in many ways. 
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